Interim results from a multicenter European retrospective study presented in the PET RANO 1.0 framework suggest vorasidenib produces earlier metabolic tumor responses than structural MRI in IDH-mutant glioma. Serial amino acid PET flagged partial responses sooner, shifting response classification relative to RANO 2.0 MRI. Among 50 patients assessed by RANO 2.0 criteria and those with baseline PET, a partial response was recorded in 29% using PET RANO 1.0 versus 6% on RANO 2.0. The median time to response was four months with PET RANO 1.0 compared with eight months using MRI-based criteria. The investigators reported that change in metabolic tumor volume was the dominant early discriminator, spanning from complete metabolic resolution to marked increases in patients classified as progressive by PET. The work argues that PET may better capture early treatment effect when MRI tumor volume changes slowly. If validated prospectively, PET-based early endpoints could improve trial decision-making for IDH-mutant glioma and guide therapy adjustments before structural progression becomes measurable.
Get the Daily Brief